外周血CD4+CD25high Treg比例变化对ALL预后判断的价值

doi:10.3969/j.issn.1673-8640.2019.04.008

检验医学 ›› 2019, Vol. 34 ›› Issue (4): 327-330.DOI: 10.3969/j.issn.1673-8640.2019.04.008

外周血CD4⁺CD25^highTreg比例变化对ALL预后判断的价值

赵莲¹, 何金龙¹, 巫翠云², 周海燕³, 周威伦⁴, 巫翠萍¹()

1.海南医学院第一附属医院检验科,海南海口 570102
2．海口市人民医院检验科,海南海口 570208
3.海南医学院第一附属医院血液肿瘤内科, 海南海口 570102
4.海南医学院第一附属医院儿科,海南海口 570102

收稿日期:2018-05-10 出版日期:2019-04-30 发布日期:2019-05-17
作者简介:null
作者简介：赵莲,女,1982年生,学士,主管技师,主要从事临床检验工作。

Role of peripheral blood CD4⁺CD25^highTreg percentage in the prognosis of ALL

ZHAO Lian¹, HE Jinlong¹, WU Cuiyun², ZHOU Haiyan³, ZHOU Weilun⁴, WU Cuiping¹()

1. Department of Clinical Laboratory,the First Affiliated Hospital of Hainan Medical College,Haikou 570102,Hainan,China
2. Department of Clinical Laboratory,Haikou People's Hospital,Haikou 570208,Hainan,China
3. Department of Oncology and Hematology,the First Affiliated Hospital of Hainan Medical College,Haikou 570102,Hainan,China
4. Department of Pediatrics,the First Affiliated Hospital of Hainan Medical College,Haikou 570102,Hainan,China

Received:2018-05-10 Online:2019-04-30 Published:2019-05-17

摘要/Abstract

摘要：

目的探讨急性淋巴细胞白血病（ALL）患者治疗前、后外周血CD4⁺CD25^high调节性T细胞（Treg）比例的变化。方法采用流式细胞术检测22例ALL患者治疗前及用长春新碱+柔红霉素+环磷酰胺+泼尼松（VDCP）方案治疗后的外周血CD4⁺CD25^highTreg比例。对所有患者随访5年,将13例持续完全缓解（CR）者作为CR组,将9例未缓解（NR）或缓解后5年内复发者作为NR组,以20名体检健康者作为正常对照组。结果与正常对照组比较,ALL组治疗前、后外周血CD4⁺CD25^highTreg比例均升高（P<0.05）,CR组治疗前外周血CD4⁺CD25^highTreg比例明显升高（P<0.001）,NR组治疗前则差异无统计学意义（P>0.05）。ALL组治疗后外周血CD4⁺CD25^highTreg比例稍低于治疗前,但差异无统计学意义（P>0.05）。CR组治疗后外周血CD4⁺CD25^highTreg比例明显低于治疗前（P<0.01）,接近于正常对照组（P>0.05）。NR组治疗后外周血CD4⁺CD25^highTreg比例明显高于治疗前（P<0.01）,且明显高于正常对照组（P<0.001）。结论外周血CD4⁺CD25^highTreg或许可作为ALL患者疗效监测的指标。

关键词: 调节性T淋巴细胞, 流式细胞术, 急性淋巴细胞白血病, 预后

Abstract:

Objective To investigate the percentage changes of peripheral blood CD4⁺CD25^high regulatory T cells（Treg） in patients with acute lymphoblastic leukemia（ALL） before and after treatment. Methods Flow cytometry was used to determine CD4⁺CD25^high Treg percentage in peripheral blood of 22 ALL patients before and after treatment [vincristine,daunorubicin,cyclophosphamide and prednisone（VDCP）]. After 5-year follow-up,13 cases achieved complete remission（CR）（CR group）,and 9 cases of non-remission（NR）（NR group） were enrolled. Totally,20 healthy subjects were enrolled as healthy control group. Results Compared with healthy control group,the percentage of CD4⁺CD25^high Treg in peripheral blood increased before and after treatment in ALL group（P<0.05）. The percentage of CD4⁺CD25^high Treg in CR group was increased（P<0.001）,while NR group had no statistical significance before treatment（P>0.05）. The percentage of CD4⁺CD25^high Treg after treatment was slightly lower in ALL group than that before treatment without statistical significance（P>0.05）. The percentage of CD4⁺CD25^high Treg after treatment was lower in CR group than that before treatment（P<0.01）,and it was close to that in healthy control group（P>0.05）. The percentage of CD4⁺CD25^high Treg after treatment in NR group was higher than that before treatment（P<0.01）,and it was higher than that in healthy control group（P<0.001）. Conclusions CD4⁺CD25^high Treg in peripheral blood may be used as an indicator for the treatment efficiency of ALL.

Key words: Regulatory T cell, Flow cytometry, Acute lymphoblastic leukemia, Prognosis

中图分类号:

R446.1

赵莲, 何金龙, 巫翠云, 周海燕, 周威伦, 巫翠萍. 外周血CD4⁺CD25^highTreg比例变化对ALL预后判断的价值[J]. 检验医学, 2019, 34(4): 327-330.

ZHAO Lian, HE Jinlong, WU Cuiyun, ZHOU Haiyan, ZHOU Weilun, WU Cuiping. Role of peripheral blood CD4⁺CD25^highTreg percentage in the prognosis of ALL[J]. Laboratory Medicine, 2019, 34(4): 327-330.

图/表 1

参考文献 16

[1]	APOSTOLOU I,VON BOEHMER H.In vivo instruction of suppressor commitment in naive T cells[J]. J Exp Med,2004,199(10):1401-1408.
[2]	巫翠萍,覃西,巫翠云,等.急性淋巴细胞白血病患者CD4+CD25+T调节细胞水平与白细胞介素2,白细胞介素10,转化生长因子β的检测[J].中国组织工程研究,2012,16(14):2648-2651.
[3]	张之南. 血液病诊断及疗效标准[M]. 天津:天津科学技术出版社,1991:106.
[4]	徐翀,关明,将黎敏,等. CD4+Foxp3+调节性T淋巴细胞在儿童急性白血病中的表达及其与微小残留病的关系[J]. 中华检验医学杂志,2009,32(3):321-325.
[5]	陆春伟,佟海侠,陆美言. 肿瘤患者外周血调节性T细胞的检测及临床意义[J]. 现代肿瘤医学,2011,19(7):1414-1416.
[6]	FONTENOT J D,RASMUSSEN J P,GAVIN M A,et al.A function for interleukin 2 in Foxp3-expressing regulatory T cells[J]. Nat Immunol,2005,6(11):1142-1151.
[7]	BAECHER-ALLAN C,BROWN J A,FREEMAN G J,et al.CD4+CD25high regulatory cells in human peripheral blood[J]. J Immunol,2001,167(3):1245-1253.
[8]	巫翠萍,覃西,王华民,等. 慢性乙型肝炎患者外周血CD4+CD25+Treg与CD4+CD8+T细胞亚群的相关研究[J]. 中国免疫学杂志,2010,26(3):273-277.
[9]	GONZALEZ-GAY M A,DE MATIAS J M,GONZALEZ-JUANATEY C,et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis[J]. Clin Exp Rheumatol,2006,24(1):83-86.
[10]	吴丕六. 小儿白血病病因学研究进展[J]. 医学信息,2015,28(43):451.
[11]	KONO K,KAWAIDA H,TAKAHASHI A,et al.CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers[J]. Cancer Immunol Immunother,2006,55(9): 1064-1071.
[12]	CESANA G C,DERAFFELE G,COHEN S,et al.Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma[J]. J Clin Oncol,2006,24(7):1169-1177.
[13]	BEYER M,KOCHANEK M,DARABI K,et al.Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine[J]. Blood,2005,106(6): 2018-2025.
[14]	CARRERAS J,LOPEZ-GUILLERMO A,FOX B C,et al.High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma[J]. Blood,2006,108(9):2957-2964.
[15]	ALVARO T,LEJEUNE M,SALVADÓ M T,et al.Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells[J]. Clin Cancer Res,2005,11(4):1467-1473.
[16]	GHIRINGHELLI F,MENARD C,PUIG P E,et al.Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients[J]. Cancer Immunol Immunother,2007,56(5): 641-648.

外周血CD4⁺CD25^highTreg比例变化对ALL预后判断的价值

Role of peripheral blood CD4⁺CD25^highTreg percentage in the prognosis of ALL

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 16

相关文章 15

编辑推荐

Metrics

组别	例数	CD4⁺CD25^highTreg
正常对照组	20	3.83（3.43~4.54）
ALL组
治疗前	22	5.49（4.18~6.46）^**
治疗后	22	4.69（3.92~5.97）^*
CR组
治疗前	13	5.67（4.82~6.49）^**
治疗后	13	3.98（3.74~4.70）^#
NR组
治疗前	9	4.23（3.30~6.84）
治疗后	9	5.70（4.96~8.55）^***#

[1]	王杨淑怡, 叶威, 林志豪, 黄约诺, 方涛, 董晓亭. 肺腺癌焦亡相关特征模型的构建和验证[J]. 检验医学, 2023, 38(9): 833-841.
[2]	张寒, 李军, 刘小江, 管义祥. 白蛋白、白细胞介素6和铁蛋白联合检测在评估自发性脑出血患者功能预后中的价值[J]. 检验医学, 2023, 38(8): 713-718.
[3]	张娜, 牛伟华, 孙媛媛, 贾玫. CMV和EBV共感染可影响造血干细胞移植患者预后[J]. 检验医学, 2023, 38(8): 760-765.
[4]	郭洁, 李海霞, 李小云. 术前外周血红细胞分布宽度/血小板计数比值与子宫内膜癌患者预后的相关性[J]. 检验医学, 2023, 38(7): 675-679.
[5]	王腾飞, 陈珊, 安和兵, 周蕾. 急性白血病患者外周血lncRNA CRNDE、miR-384表达及其临床意义[J]. 检验医学, 2023, 38(7): 686-691.
[6]	张春玲, 蔺丽慧, 王小蕊, 丁静, 李莉. 成人KMT2A/MLLT6阳性急性髓系白血病1例报道并文献复习[J]. 检验医学, 2023, 38(7): 704-706.
[7]	尹娅, 潘沅, 周宏伟, 沈薇. BNP和NT-proBNP在新生儿心血管疾病中的应用进展[J]. 检验医学, 2023, 38(6): 518-523.
[8]	赵婧, 王佩, 卢丹丹, 齐丹丹, 李轩. 出血性脑卒中患者血清miR-4443、TRAF4相对表达量变化的临床意义[J]. 检验医学, 2023, 38(5): 413-418.
[9]	宋世伟, 李景武, 林韬, 刘泽宇, 王志强, 孙卫东. GPNMB与非小细胞肺癌患者肿瘤免疫浸润和预后的相关性[J]. 检验医学, 2023, 38(4): 347-351.
[10]	刘俊闪, 郭明发, 孙佳, 史利欢, 刘炜, 段勇涛. 微量残留病监测在ETV6/RUNX1阴性和阳性急性B淋巴细胞白血病患儿预后中的意义[J]. 检验医学, 2023, 38(3): 209-214.
[11]	陈哲, 张灵, 刘洁, 王霞, 张斌, 高炳华. 血清miR-326与治疗相关性血液系统恶性肿瘤患者化疗敏感性和预后的关系[J]. 检验医学, 2023, 38(3): 251-256.
[12]	李志霞, 肖华, 卓芬, 李存盈, 李绍武, 王玉丰. 外周血LYMPH#、MO#、LMR在DLBCL患者预后评估中的价值[J]. 检验医学, 2023, 38(12): 1198-1201.
[13]	顾怡, 王蕊, 邓杰, 杨易静, 周王柯, 陈予诺, 陈小松, 沈薇, 周景艺. 重症肝炎和肝硬化患者肝移植前后生物标志物水平差异及其预后评估价值[J]. 检验医学, 2023, 38(11): 1044-1051.
[14]	梁卫章, 石建平, 柴丽娜, 韩爱子. 血清组织蛋白酶K、解聚蛋白样金属蛋白酶-7与慢性心力衰竭患者心室重构和预后的关系[J]. 检验医学, 2023, 38(10): 919-925.
[15]	周军, 李立恒, 张敏. 口腔腺样囊性癌患者血清miR-24、XIAP mRNA表达及其与预后的相关性[J]. 检验医学, 2023, 38(10): 930-935.

外周血CD4+CD25high Treg比例变化对ALL预后判断的价值

Role of peripheral blood CD4+CD25high Treg percentage in the prognosis of ALL

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 16

相关文章 15

编辑推荐

Metrics

外周血CD4⁺CD25^highTreg比例变化对ALL预后判断的价值

Role of peripheral blood CD4⁺CD25^highTreg percentage in the prognosis of ALL